Lisa D. Earnhardt's most recent trade in Abbott Laboratories was a trade of 91,167 Common shares without par value done at an average price of $81.0 . Disclosure was reported to the exchange on March 6, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Abbott Laboratories | Lisa D. Earnhardt | EVP AND GROUP PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 80.98 per share. | 06 Mar 2025 | 91,167 | 163,095 (0%) | 0% | 81.0 | 7,382,704 | Common shares without par value |
Abbott Laboratories | Lisa D. Earnhardt | EVP AND GROUP PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 91,167 | 200 | - | - | Option (right to buy) | |
Abbott Laboratories | Lisa D. Earnhardt | EVP AND GROUP PRESIDENT | Sale of securities on an exchange or to another person at price $ 133.82 per share. | 06 Mar 2025 | 91,167 | 71,928 (0%) | 0% | 133.8 | 12,199,968 | Common shares without par value |
Abbott Laboratories | Lisa D. Earnhardt | EVP AND GROUP PRESIDENT | Sale of securities on an exchange or to another person at price $ 136.64 per share. | 06 Mar 2025 | 200 | 71,928 (0%) | 0% | 136.6 | 27,329 | Common shares without par value |
Abbott Laboratories | Lisa D. Earnhardt | EVP AND GROUP PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 200 | 0 | - | - | Option (right to buy) | |
Abbott Laboratories | Lisa D. Earnhardt | EVP AND GROUP PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 80.98 per share. | 06 Mar 2025 | 200 | 72,128 (0%) | 0% | 81.0 | 16,196 | Common shares without par value |
Abbott Laboratories | Lisa D. Earnhardt | EVP AND GROUP PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 135.87 per share. | 28 Feb 2025 | 8,322 | 71,928 (0%) | 0% | 135.9 | 1,130,710 | Common shares without par value |
Abbott Laboratories | Lisa D. Earnhardt | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 69,977 | 69,977 | - | - | Option (right to buy) | |
Abbott Laboratories | Lisa D. Earnhardt | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 18,788 | 80,250 (0%) | 0% | 0 | Common shares without par value | |
Abbott Laboratories | Lisa D. Earnhardt | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 106.25 per share. | 07 May 2024 | 22,852 | 61,462 (0%) | 0% | 106.3 | 2,428,119 | Common shares without par value |
Abbott Laboratories | Lisa D. Earnhardt | EXECUTIVE VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 120.05 per share. | 29 Feb 2024 | 7,669 | 85,008 (0%) | 0% | 120.0 | 920,663 | Common shares without par value |
Abbott Laboratories | Lisa D. Earnhardt | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 118.50 per share. | 29 Feb 2024 | 694 | 84,314 (0%) | 0% | 118.5 | 82,239 | Common shares without par value |
Abbott Laboratories | Earnhardt Lisa D. | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 64,787 | 64,787 | - | - | Option (right to buy) | |
Abbott Laboratories | Lisa Earnhardt D. | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 17,240 | 92,677 (0%) | 0% | 0 | Common shares without par value | |
Abbott Laboratories | Lisa D. Earnhardt | EXECUTIVE VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 99.77 per share. | 28 Feb 2023 | 7,631 | 76,380 (0%) | 0% | 99.8 | 761,345 | Common shares without par value |
Abbott Laboratories | Lisa D. Earnhardt | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 100.70 per share. | 28 Feb 2023 | 943 | 75,437 (0%) | 0% | 100.7 | 94,960 | Common shares without par value |
Abbott Laboratories | Lisa D. Earnhardt | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 62,527 | 62,527 | - | - | Option (right to buy) | |
Abbott Laboratories | Lisa D. Earnhardt | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 15,855 | 84,011 (0%) | 0% | 0 | Common shares without par value | |
Abbott Laboratories | Lisa D. Earnhardt | EXECUTIVE VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 112.71 per share. | 10 Jun 2022 | 19,592 | 68,156 (0%) | 0% | 112.7 | 2,208,214 | Common shares without par value |
Abbott Laboratories | Lisa D. Earnhardt | EXECUTIVE VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 112.71 per share. | 10 Jun 2022 | 2,882 | 87,748 (0%) | 0% | 112.7 | 324,830 | Common shares without par value |
Abbott Laboratories | Lisa D. Earnhardt | EXECUTIVE VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 122.41 per share. | 28 Feb 2022 | 5,168 | 91,573 (0%) | 0% | 122.4 | 632,615 | Common shares without par value |
Abbott Laboratories | Lisa D. Earnhardt | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 118.15 per share. | 28 Feb 2022 | 943 | 90,630 (0%) | 0% | 118.2 | 111,416 | Common shares without par value |
Abbott Laboratories | Lisa D. Earnhardt | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2022 | 80,380 | 80,380 | - | - | Option (right to buy) | |
Abbott Laboratories | Lisa D. Earnhardt | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2022 | 17,247 | 96,741 (0%) | 0% | 0 | Common shares without par value | |
Abbott Laboratories | Lisa D. Earnhardt | EXECUTIVE VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 109.05 per share. | 10 Jun 2021 | 2,881 | 79,494 (0%) | 0% | 109.0 | 314,173 | Common shares without par value |
Abbott Laboratories | Lisa D. Earnhardt | EXECUTIVE VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 121.58 per share. | 26 Feb 2021 | 2,621 | 83,318 (0%) | 0% | 121.6 | 318,661 | Common shares without par value |
Abbott Laboratories | Lisa D. Earnhardt | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 120.61 per share. | 26 Feb 2021 | 943 | 82,375 (0%) | 0% | 120.6 | 113,735 | Common shares without par value |
Abbott Laboratories | Lisa D. Earnhardt | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2021 | 71,070 | 71,070 | - | - | Option (right to buy) | |
Abbott Laboratories | Lisa D. Earnhardt | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2021 | 13,865 | 85,939 (0%) | 0% | 0 | Common shares without par value | |
Abbott Laboratories | Lisa D. Earnhardt | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 90.27 per share. | 10 Jun 2020 | 2,855 | 72,946 (0%) | 0% | 90.3 | 257,721 | Common shares without par value |
Abbott Laboratories | Lisa D. Earnhardt | Executive Vice President | Sale of securities on an exchange or to another person at price $ 90.84 per share. | 10 Jun 2020 | 872 | 72,074 (0%) | 0% | 90.8 | 79,216 | Common shares without par value |